Grants for Public housing authorities - Health

The purpose of the Mentored Research Scientist Career Development Award in Tobacco Regulatory Research (K01) is to provide support and protected time (three, four, or five years) for an intensive, supervised career development experience in biomedical, behavioral, and social science research that will inform the development and evaluation of regulations on tobacco product manufacturing, distribution, and marketing and that will lead to research independence. Research projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP) as mandated by the Family Smoking Prevention and Tobacco Control Act (FSPTCA), Public Law 111-31.

The National Institute on Alcohol Abuse and Alcoholism ( NIAAA) intends to reissue RFA-AA-23-001, Specialized Alcohol Research Centers (P50, Clinical Trial Optional), by publishing a NOFO to solicit applications for a broad-based Alcohol Research Centers program to foster and conduct interdisciplinary, collaborative research on Alcohol Use Disorder (AUD), alcohol misuse and alcohol-related problems, and other health-related consequences across the lifespan. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. The NOFO is expected to be published in Spring 2024 with an expected application due date in Fall 2024. This NOFO will utilize the P50 activity code. Details of the planned NOFO are provided below.

The NIH Directors Pioneer Award Program supports individual scientists of exceptional creativity who propose bold and highly innovative research projects with the potential to produce a major impact on broad, important areas relevant to the mission of NIH. To support innovative and novel research across the vast NIH mission, individuals from diverse backgrounds (including those from underrepresented groups; see Notice of NIHs Interest in Diversity) and from the full spectrum of eligible institutions in all geographic locations are encouraged to apply to this Notice of Funding Opportunity. Applications in all topics relevant to the broad mission of NIH are welcome, including, but not limited to, topics in the behavioral, social, biomedical, applied, and formal sciences and topics that may involve basic, translational, or clinical research. The NIH Directors Pioneer Award is a component of the High-Risk, High-Reward Research (HRHR) Program of the NIH Common Fund.

This funding opportunity provides financial support to organizations implementing strategies to prevent diabetes and improve health equity for populations at risk, focusing on statewide, local, or multisectoral approaches.

This funding opportunity supports research centers focused on understanding how biological sex differences affect women's health, promoting interdisciplinary collaboration and workforce diversity in the scientific community.

This funding opportunity supports the establishment of a center that fosters collaboration between researchers in substance use epidemiology and prevention to develop effective strategies for preventing substance use and related issues.

Synopsis: NOFO # DD24-0051 solicits non-research, cooperative agreement applications to conduct population-based surveillance of congenital heart defects (CHD) to describe health outcomes including health equity, with the goal of identifying opportunities to improve the health of all people living with CHD. This project will involve a required component (A) and an optional component (B). The population included in this surveillance activity can be an entire state or a region within a state. Individuals with CHD should be identified through existing data sources including the jurisdiction birth defects surveillance system, electronic health records, administrative data (e.g., Medicaid/Medicare, hospital discharge), or other sources available to funding recipients. Background: Congenital heart defects (CHD) affect about 1% of all births in the United States, and are a leading cause of birth defect-associated infant mortality, morbidity, and healthcare costs. Improvements in early detection and treatment of CHD and consequently in survival have resulted in many people, including those affected by a severe CHD, living into adolescence and adulthood. An estimated two million persons in the U.S. are living with a CHD, including over one million adults; about 12% of these affected adults have a severe CHD. Most current efforts to conduct population-based surveillance of CHD have focused on monitoring newborns. However, little data exist on the descriptive epidemiology of CHD beyond early childhood in the U.S. Despite the public health burden, the lack of population-based surveillance precludes reliable data on people with CHD, their survival, healthcare utilization, and characteristics associated with long-term outcomes. Through this surveillance activity, these data will be assessed, enabling and informing efforts to improve the health and well-being of people with CHD. Objectives: Component A objectives include: (1) assess survival, comorbidities, healthcare utilization during the period 2021-2023, and characteristics associated with long-term outcomes among people with CHD; (2) assess health equity among people with CHD; (3) examine state and national healthcare policies that have an impact on people with CHD; (4) examine COVID-19 and related data such as health care utilization during the pandemic among people with CHD; and (5) work with local/state partners to use site-specific CHD data. Component B objectives include: (1) develop and refine a machine learning algorithm for the surveillance data collected through Component A; and (2) apply this machine learning algorithm to data collected from all recipients funded through Component A.

This funding opportunity supports experienced researchers looking to expand their expertise or shift their career focus through advanced training and research experiences at various institutions.

This funding opportunity supports innovative research into the biological mechanisms behind complex brain disorders, targeting a wide range of eligible applicants including universities, nonprofits, and small businesses.

This funding opportunity supports a wide range of organizations in developing innovative drug therapies for Alzheimer's disease and related dementias, focusing on non-traditional treatment targets and requiring collaboration with NIH throughout the clinical trial process.

This funding opportunity supports innovative research into new risk factors for liver cancer, particularly focusing on non-viral causes and their interactions with established risks, aimed at improving prevention strategies in the U.S. population.

This funding opportunity provides financial support for researchers and organizations to investigate the factors driving tuberculosis transmission and develop innovative methods for prevention and detection in high-burden areas.

This funding opportunity supports initiatives that plan to improve health equity and reduce health disparities for women and girls of reproductive age from racial and ethnic minority and underserved communities by integrating comprehensive healthcare services.

This funding opportunity provides financial support for U.S.-based researchers and institutions to develop innovative human models that simulate radiation injuries, aiming to improve understanding and treatment of radiation exposure effects.

The Silvio O. Conte Digestive Diseases Research Core Centers grant, provided by the NIDDK, supports collaborative research on digestive and liver diseases by offering shared resources to enhance productivity and foster new ideas, centered around a theme within the NIDDK's mission.

This funding opportunity supports collaborative research projects in neurology, encouraging diverse teams to tackle significant scientific questions that advance the field through interdependent studies.

This funding opportunity supports the development of diverse cancer research cohorts to improve understanding of cancer causes and outcomes, particularly among underrepresented populations.

This funding opportunity provides support for high-risk clinical trials focused on infectious, immunologic, and allergic diseases, encouraging innovative research that can lead to new treatments and therapies.

The purpose of the Mentored Quantitative Research Career Development Award (K25) is to attract to NIH-relevant research those investigators whose quantitative science and engineering research has thus far not been focused primarily on questions of health and disease. The K25 award will provide support and "protected time" for a period of supervised study and research for productive professionals with quantitative (e.g., mathematics, statistics, economics, computer science, imaging science, informatics, physics, chemistry) and engineering backgrounds to integrate their expertise with NIH-relevant research. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA ().

This funding opportunity supports U.S.-based cancer research institutions to enhance their research infrastructure and collaborative efforts in cancer prevention, treatment, and care.